Forte Biosciences, INC Form 4 insider transactions

Director Barbara K. Finck acquired 31,000 stock options in Forte Biosciences, Inc. on March 19, 2025.

Antony A. Riley, CFO of Forte Biosciences, reports the vesting and subsequent disposal of shares to cover tax obligations.

Forte Biosciences CEO Paul Wagner reports the vesting of restricted stock units and subsequent sale of shares to cover taxes.

Forte Biosciences' Chief Financial Officer, Antony A. Riley, purchased 22,514 shares of common stock in a private placement at $5.552 per share.

Forte Biosciences CFO Antony A. Riley reports the acquisition and disposal of company stock and restricted stock units on October 1, 2024.

Paul A. Wagner, CEO of Forte Biosciences, reports the vesting and disposal of restricted stock units and common stock transactions.

Shivpreet Singh Kapoor, a director at Forte Biosciences, acquired stock options for 2,000 shares on September 17, 2024.

Director Richard G. Vincent of Forte Biosciences acquired 2,000 stock options on September 17, 2024, according to a Form 4 filing with the SEC.

Director Lawrence Eichenfield of Forte Biosciences acquired 50,000 stock options on August 20, 2024, according to a Form 4 filing.

Director David W. Gryska acquired 50,000 stock options in Forte Biosciences, Inc. on August 20, 2024.

Director Steven Kornfeld acquired 50,000 stock options in Forte Biosciences, Inc. on August 20, 2024.

Director Stephen K. Doberstein acquired 50,000 stock options in Forte Biosciences, Inc. on August 20, 2024.

Director Barbara K. Finck acquired 50,000 stock options in Forte Biosciences, Inc. on August 20, 2024, according to a Form 4 filing.

Director Donald Allen Williams acquired 50,000 stock options in Forte Biosciences, Inc. on August 20, 2024.

Director Scott C. Brun acquired 50,000 stock options in Forte Biosciences, Inc. on August 20, 2024.

Forte Biosciences CFO Antony A. Riley reports the vesting and subsequent disposal of restricted stock units.

Paul A. Wagner, CEO of Forte Biosciences, reports the vesting and disposal of restricted stock units and common stock.

Forte Biosciences CFO Antony A. Riley reports the acquisition and disposal of company stock and restricted stock units on April 1, 2024.

Paul A. Wagner, CEO of Forte Biosciences, reports the vesting of restricted stock units and subsequent disposition of shares to cover tax obligations.

Barbara K. Finck, a director of Forte Biosciences, acquired 175,000 stock options on March 21, 2024, according to a recent SEC filing.

Antony A. Riley, CFO of Forte Biosciences, Inc., reports the acquisition of 350,000 stock options on March 21, 2024.

Paul A. Wagner, CEO of Forte Biosciences, acquired 1,100,000 stock options on March 21, 2024, according to a Form 4 filing.